Speeding tumor genotyping during the SARS‐CoV‐2 outbreak through liquid biopsy
- 30 May 2020
- Vol. 126 (18), 4089-4091
- https://doi.org/10.1002/cncr.32983
Abstract
This commentary proposes a shift in the current diagnostic workflow for patients with metastatic cancer to incorporate the use of liquid biopsy. This proposal, born in the time of a severe crisis for the health care system, might also be applied when the severe acute respiratory syndrome coronavirus 2 outbreak ends and thereby reduce the turnaround time for results from molecular testing for patients with cancer and increase the number of patients potentially benefiting from highly effective targeted therapies.Keywords
This publication has 14 references indexed in Scilit:
- SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, ChinaJAMA Oncology, 2020
- Fewer cancer diagnoses during the COVID-19 epidemic in the NetherlandsThe Lancet Oncology, 2020
- Safety at the Time of the COVID-19 Pandemic: How to Keep Our Oncology Patients and Healthcare Workers SafeJournal of the National Comprehensive Cancer Network, 2020
- Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemicNature Reviews Clinical Oncology, 2020
- Managing COVID-19 in the oncology clinic and avoiding the distraction effectAnnals of Oncology, 2020
- Cancer patients in SARS-CoV-2 infection: a nationwide analysis in ChinaThe Lancet Oncology, 2020
- Prospective Clinical Validation of the InVisionFirst-Lung Circulating Tumor DNA Assay for Molecular Profiling of Patients With Advanced Nonsquamous Non–Small-Cell Lung CancerJCO Precision Oncology, 2019
- Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung CancerClinical Cancer Research, 2019
- Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast CancerThe New England Journal of Medicine, 2019
- Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLCJournal of Thoracic Oncology, 2018